Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Insights
Takeda’s takeover of Shire (CNBC)
Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Related
Insights
How to Power Pharma and Biotech R&D with Sharp Commercial Insights
DiscoverThe Novasecta European MidPharma Report 2022
DiscoverPharma/Biotech R&D Effectiveness: What it Takes – Exclusive Workshop
Discover